| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,005 | 0,045 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | XFRA 4A1: WIEDERAUFNAHME/RESUMPTION | 159 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 04.11. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q3 2026 | 177 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 03.11. | XFRA 4A1: AUSSETZUNG/SUSPENSION | 229 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCERENO SCIENTIFIC... ► Artikel lesen | |
| 03.11. | Suspension of Trading in Cereno Scientific AB at FNSE | 583 | GlobeNewswire | 2026-11-03T12:17:09ZSuspensionAt Trading Venue FNSEDue to Non Disclosure Of Inside Information About The Issuer Or Financial InstrumentOngoing: TrueComments: Nasdaq Stockholm has, to the extent applicable... ► Artikel lesen | |
| 02.11. | Cereno Scientific AB: Cereno Scientific Sees Strong Investigator Engagement as EPIMODE Phase IIb Trial Advances | 199 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 08.10. | Cereno Scientific AB: Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results | 293 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides an update... ► Artikel lesen | |
| 25.09. | Cereno Scientific AB: Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD | 687 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 26.08. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2026 | 653 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 13.08. | Cereno Scientific AB: Cereno Scientific Activates First Clinical Site in Global Phase IIb EPIMODE Trial of CS1 in PAH, Enabling Patient Recruitment | 410 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for rare cardiovascular and pulmonary diseases, today announced that the first... ► Artikel lesen | |
| 08.07. | Cereno Scientific AB: Cereno Scientific Confirms that Members of Management and Chair of Board have Acquired Shares for a Total of Over 1.5 MSEK | 398 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that... ► Artikel lesen | |
| 26.06. | Cereno Scientific AB: Cereno Scientific Reports EAP Analyses with CS1 in PAH: Majority of Completing Patients Achieved Stable or Improved Clinical Status over 12 Months | 419 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), a biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today reported further analyses... ► Artikel lesen | |
| 17.06. | Cereno Scientific AB: Cereno Scientific AB (publ) publishes report from the Annual General Meeting 2026 | 581 | GlobeNewswire (Europe) | Today, June 17, 2026, Cereno Scientific AB (publ) held its Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairperson of the Annual General Meeting... ► Artikel lesen | |
| 27.05. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q1 2026 | 1.306 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 11.05. | Cereno Scientific AB: Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension | 591 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a collaboration... ► Artikel lesen | |
| 04.04. | Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH | 1.032 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides additional... ► Artikel lesen | |
| 31.03. | Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | 580 | PR Newswire | GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 23.03. | Cereno Scientific - Inflection points coming into view | 1.058 | Edison Investment Research | Cereno Scientific's FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226... ► Artikel lesen | |
| 19.03. | Cereno Scientific - capital markets day highlights (Video) | 1.006 | Edison Investment Research | In this video, we go behind the scenes at Cereno Scientific's capital markets day, speaking with key stakeholders, including company leadership, industry experts and patients living with pulmonary arterial... ► Artikel lesen | |
| 17.03. | Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | 967 | PR Newswire | GOTHENBURG, Sweden, March 17, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.02. | Cereno Scientific AB: Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025) | 1.055 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ACTIVE BIOTECH | 0,265 | -0,75 % | Active Biotech AB: Active Biotech Interim Report Q3 2026 | EVENTS DURING THE THIRD QUARTERFirst patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis (July 24)Active Biotech expanded US collaboration to advance tasquinimod clinical... ► Artikel lesen | |
| CANTARGIA | 0,085 | -9,42 % | Cantargia Announces IL-17 as Second Target for Bispecific CAN14 Antibody | LUND, SE / ACCESS Newswire / November 9, 2026 / Cantargia AB (publ) (STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced IL-17... ► Artikel lesen | |
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Why Recursion Pharmaceuticals Stock Is Up Today | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 |